[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.
Shan, Weifang; Balog, Aaron; Nation, Andrew; Zhu, Xiao; Chen, Jing; Cvijic, Mary Ellen; Geng, Jieping; Rizzo, Cheryl A; Spires, Thomas; Attar, Ricardo M; Obermeier, Mary; Traeger, Sarah; Dai, Jun; Zhang, Yingru; Galella, Michael; Trainor, George; Vite, Gregory D; Gavai, Ashvinikumar V.
Bioorg Med Chem Lett
; 26(23): 5707-5711, 2016 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-27836399
Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif.
Bicyclo((aryl)methyl)benzamides as inhibitors of GlyT1.
Heterocyclic modification of a novel bicyclo[3.1.0]hexane NPY1 receptor antagonist.
SelexGLM differentiates androgen and glucocorticoid receptor DNA-binding preference over an extended binding site.
Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor.
Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead.
Influence of chain length on the activity of tripeptidomimetic antagonists for CXC chemokine receptor 4 (CXCR4).
Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.
Novel bicyclo[3.1.0]hexane analogs as antagonists of metabotropic glutamate 2/3 receptors for the treatment of depression.
Substituted fused bicyclic pyrrolizinones as potent, orally bioavailable hNK1 antagonists.